For decades, animal testing has been central to evaluating drug safety, but the field is entering a period of major change. New alternative methods (NAMs) are gaining momentum as regulators and researchers look for more human-relevant ways to predict toxicity while reducing reliance on animal models.

In this Tell Us What You Know episode, Jonny Sexton from the University of Michigan discusses how his lab combines human liver organoids and liver-on-chip systems with high-content imaging to detect subtle toxic effects earlier, before drugs reach clinical trials.

Watch this episode to learn:

• What NAMs are and why they matter for drug safety
• How liver organoids and liver-on-chip models improve drug toxicity prediction
• The role of high-content imaging in revealing hidden toxic effects and drug–drug interactions